Company Kanabo Group Plc

KNB

GB00BYQCS703

Pharmaceuticals

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:20 2024-04-26 am EDT			5-day change	1st Jan Change
1.7 ^GBX	0.00%		+2.10%	-39.29%

Mar. 28	Kanabo shares soar after company announces UK mental health service	AN
Mar. 28	Kanabo Group plc Announces Expansion of Treat It Clinic to Offer Mental Health Treatments	CI

Kanabo Group plc is a United Kingdom-based patient-focused provider of digital health services and specialist medicines, including medicinal cannabis. The Companyâs principal activities are the distribution and development of cannabis derived medical and wellness products. The Company is focused on the distribution of cannabis-derived products for medical patients, and non- tetrahydrocannabinol (THC) products for cannabidiol (CBD) consumers. It has conducted research and development (R&D) in order to develop cannabis extract formulas, medical-grade vaporizers and various non-smoking consumption solutions. Its clinical and validation activities, including safety and efficiency tests, are conducted in Israel. The Company operates through two segments: Primary case and Secondary case. Primary case segment is involved in the telepharma services provided by GPS. Secondary case segment is involved in the distribution and development of cannabis-derived medical and wellness products.

Number of employees: 23

Managers	Title	Age	Since
Avihu Tamir CEO	Chief Executive Officer	-	-
Assaf Vardimon DFI	Director of Finance/CFO	46	-
Ophir Shimshi COO	Chief Operating Officer	-	-
Suleman Sacranie PRN	Corporate Officer/Principal	35	-

Members of the board	Title	Age	Since
Ian Mattioli CHM	Chairman	62	23-05-08
David Tsur BRD	Director/Board Member	73	21-06-27
Sharon Malka BRD	Director/Board Member	51	23-05-03
Avihu Tamir CEO	Chief Executive Officer	-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	632,427,870	322,120,048 ( 50.93 %)	0	50.93 %

Name	Equities	%	Valuation
Avihu Tamir 15.38 %	97,263,870	15.38 %	2 M p
ICU Holdings Ltd. 10.98 %	69,444,444	10.98 %	2 M p
Maven Capital Partners UK LLP 7.747 %	48,993,386	7.747 %	1 M p
David Sack 2.268 %	14,341,080	2.268 %	317 081 p
David Tsur 1.433 %	9,061,102	1.433 %	200 341 p
Andrew John Gowdy Morrison 0.7274 %	4,600,080	0.7274 %	101 708 p
Uziel Danino 0.5824 %	3,683,382	0.5824 %	81 440 p
Daniel Poulter 0.008697 %	55,000	0.008697 %	1 216 p
Gil Efron 0.000000 %	0	0.000000 %	- p

Kanabo Group Plc

Churchill House 137-139 Brent Street

NW4 4DJ, London

http://www.kanabogroup.com

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
KANABO GROUP PLC	-39.29%	13.43M
ELI LILLY AND COMPANY	+26.17%	653B
NOVO NORDISK A/S	+27.00%	556B
JOHNSON & JOHNSON	-6.78%	354B
MERCK & CO., INC.	+20.76%	331B
ABBVIE INC.	+1.90%	296B
ASTRAZENECA PLC	+13.09%	233B
NOVARTIS AG	+5.46%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-6.13%	144B